{"log_id": 2047262633961021124, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 1.2e-05, "average": 0.997726, "min": 0.987559}, "location": {"width": 510, "top": 229, "height": 27, "left": 248}, "words": "产程和分娩:文拉法辛对于人类产程和分娩过程的作用不明"}, {"probability": {"variance": 0.005282, "average": 0.959038, "min": 0.813867}, "location": {"width": 104, "top": 276, "height": 24, "left": 231}, "words": "非致畸作用"}, {"probability": {"variance": 0.000467, "average": 0.989844, "min": 0.911002}, "location": {"width": 759, "top": 317, "height": 29, "left": 249}, "words": "妊娠后3个月的胎儿暴露在本品、其它 SNRIS(5HT和去甲肾上腺素再摄取抑制剂)或"}, {"probability": {"variance": 0.000914, "average": 0.990419, "min": 0.855562}, "location": {"width": 778, "top": 362, "height": 31, "left": 229}, "words": " SSRIS治疗的环境下,分娩后住院时间延长、呼吸支持和胃管喂养的并发症增多。报告的临"}, {"probability": {"variance": 0, "average": 0.99598, "min": 0.99598}, "location": {"width": 37, "top": 351, "height": 25, "left": 1073}, "words": "局"}, {"probability": {"variance": 0.000963, "average": 0.990258, "min": 0.838903}, "location": {"width": 759, "top": 408, "height": 30, "left": 229}, "words": "床表现还包括呼吸窘迫、紫绀、肌张力增高/降低、体温不稳定、喂养困难、呕吐、低血糖"}, {"probability": {"variance": 0.001497, "average": 0.98491, "min": 0.811087}, "location": {"width": 779, "top": 455, "height": 27, "left": 229}, "words": "反射亢进、震颤、兴奋和哭泣不止等。这些表现与RIs和 SNRIS的直接毒性作用相似,也"}, {"probability": {"variance": 0.002913, "average": 0.980044, "min": 0.74413}, "location": {"width": 780, "top": 499, "height": 29, "left": 230}, "words": "可能是一种停药综合征。需要注意的是部分患者的临床表现与5HT综合征相似。当给孕期"}, {"probability": {"variance": 0.000472, "average": 0.993729, "min": 0.888151}, "location": {"width": 481, "top": 544, "height": 29, "left": 232}, "words": "后3个月的孕妇使用本品时,医生应仔细权衡治疗的利弊"}, {"probability": {"variance": 5e-06, "average": 0.982161, "min": 0.979834}, "location": {"width": 38, "top": 593, "height": 23, "left": 237}, "words": "哺乳"}, {"probability": {"variance": 1e-06, "average": 0.999194, "min": 0.997156}, "location": {"width": 397, "top": 633, "height": 29, "left": 271}, "words": "患者如果是母乳喂养婴儿,应通知她们的医生"}, {"probability": {"variance": 0.004645, "average": 0.979525, "min": 0.591133}, "location": {"width": 733, "top": 677, "height": 27, "left": 276}, "words": "报道文拉法辛和ODv可由母乳分泌。因为本品对喂养的胎儿有潜在严重不良反应的可"}, {"probability": {"variance": 2.9e-05, "average": 0.997645, "min": 0.970226}, "location": {"width": 592, "top": 723, "height": 27, "left": 232}, "words": "能,必须考虑母亲用药的必要性,并在停止哺乳和停药之间作出选择"}, {"probability": {"variance": 1.3e-05, "average": 0.995441, "min": 0.989296}, "location": {"width": 110, "top": 770, "height": 24, "left": 238}, "words": "【儿童用药"}, {"probability": {"variance": 0.000325, "average": 0.993867, "min": 0.910618}, "location": {"width": 455, "top": 814, "height": 25, "left": 272}, "words": "本品用于儿童(18岁以下)的疗效和安全性尚未证实"}, {"probability": {"variance": 0.001103, "average": 0.991415, "min": 0.826755}, "location": {"width": 739, "top": 858, "height": 26, "left": 271}, "words": "尽管有2项安慰剂对照研究中的766例抑郁症儿童和2项安慰剂对照研究中的793例儿童"}, {"probability": {"variance": 0.00135, "average": 0.991502, "min": 0.794145}, "location": {"width": 574, "top": 900, "height": 30, "left": 235}, "words": "GAD患者使用本品,但以上数据尚不足以支持该药适用于儿童患者"}, {"probability": {"variance": 9.9e-05, "average": 0.994839, "min": 0.95374}, "location": {"width": 738, "top": 945, "height": 28, "left": 273}, "words": "在儿童的临床试验中,观察到有自杀意念的不良反应发生。另外敌意和自伤的报告也增"}, {"probability": {"variance": 0.008509, "average": 0.969626, "min": 0.664073}, "location": {"width": 236, "top": 992, "height": 25, "left": 236}, "words": "多,自伤尤见于抑郁症患者"}, {"probability": {"variance": 0.008956, "average": 0.963646, "min": 0.537866}, "location": {"width": 635, "top": 1023, "height": 40, "left": 283}, "words": "任何人考虑给儿童和青少年使用本品时必须权衡临床需求和潜在风险约"}, {"probability": {"variance": 1e-05, "average": 0.99804, "min": 0.990916}, "location": {"width": 112, "top": 1082, "height": 23, "left": 238}, "words": "【老年用药】"}, {"probability": {"variance": 0.010987, "average": 0.949391, "min": 0.572967}, "location": {"width": 732, "top": 1119, "height": 31, "left": 277}, "words": "大约分别有4%(14357)和6%(7181)年龄高于65岁的治疗抑郁症和AD患者参"}, {"probability": {"variance": 0, "average": 0.740757, "min": 0.740757}, "location": {"width": 20, "top": 1148, "height": 18, "left": 938}, "words": "2"}, {"probability": {"variance": 0.008953, "average": 0.975424, "min": 0.394534}, "location": {"width": 783, "top": 1164, "height": 33, "left": 238}, "words": "上市前本品与安慰剂对照的研究。参加常释制剂治疗抑郁症上市前研究的2897例患者中12"}, {"probability": {"variance": 0.001807, "average": 0.985359, "min": 0.769043}, "location": {"width": 759, "top": 1209, "height": 29, "left": 253}, "words": "357)的患者年龄高于65岁。未发现老年患者与年轻患者在疗效、安全性方面有显著的差"}, {"probability": {"variance": 0.001424, "average": 0.985734, "min": 0.779115}, "location": {"width": 777, "top": 1255, "height": 29, "left": 235}, "words": "异,临床疗效方面也没有差异。老年患者使用本品和 SSRIS、SNRI发生低钠血症不良反应的"}, {"probability": {"variance": 1e-06, "average": 0.999305, "min": 0.997621}, "location": {"width": 81, "top": 1305, "height": 23, "left": 237}, "words": "风险更高"}, {"probability": {"variance": 0.002307, "average": 0.983733, "min": 0.740496}, "location": {"width": 735, "top": 1344, "height": 28, "left": 277}, "words": "老年患者无需根据年龄调整本品剂量。在有肾功能或肝功能不全时,应适当减量(见【用"}, {"probability": {"variance": 5.7e-05, "average": 0.991328, "min": 0.980818}, "location": {"width": 82, "top": 1394, "height": 24, "left": 235}, "words": "法用量"}, {"probability": {"variance": 1e-06, "average": 0.998987, "min": 0.996334}, "location": {"width": 150, "top": 1438, "height": 25, "left": 243}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.000504, "average": 0.992379, "min": 0.896912}, "location": {"width": 608, "top": 1478, "height": 30, "left": 287}, "words": "文拉法辛通过复杂的作用机制,有可能和其它药物产生潜在的相互作用"}, {"probability": {"variance": 0, "average": 0.997977, "min": 0.997293}, "location": {"width": 42, "top": 1526, "height": 24, "left": 240}, "words": "酒精"}], "language": 3}